Mori, Vitor
Bates, Jason H. T.
Jantz, Michael
Mehta, Hiren J.
Kinsey, C. Matthew
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (DRQ-0620)
The University of Vermont Department of Medicine
Article History
Received: 15 February 2021
Accepted: 19 November 2021
First Online: 7 January 2022
Competing interests
: JHTB is a consultant for Johnson & Johnson on matters related to this study, and is co-applicant on the patent application “Methods for computational modeling to guide intratumoral therapy.” U.S. Patent Application No. 62/542,623. Filed: August 8, 2017. CMK is a consultant for Olympus America, Johnson and Johnson, and consultant and equity holder for Quantitative Imaging Solutions. He serves on the steering committee for Nuvaira and the Scientific Advisory Board for Galvanize Therapeutics. He reports grants from the NIH, clinical trial funding through Johnson and Johnson, and is a co-applicant on the patent application "Methods for computational modeling to guide intratumoral therapy". U.S. Patent Application No. 62/542,623. Filed: August 8, 2017.” VM, MJ and HM declare that there are no conflict of interest.